Biocon Biologics signs agreement to expand access of cancer biosimilars to over 30 countries

Biocon Biologics, a fully-integrated biosimilars company and a subsidiary of Biocon Limited announced that it has signed an agreement with Clinton Health Access Initiative to expand access to lifesaving cancer biosimilars in over 30 countries in Africa and Asia as a part of Cancer Access Partnership (CAP).   

The partnership aims to deliver advanced cancer therapies to patients who need them the most while ensuring equitable access to high-quality biosimilars in low and middle-income countries (LMICs).  

Biocon Biologics’ strong R&D and manufacturing capabilities have enabled the company to offer affordable biologics such as ‘bTrastuzumab’ and ‘bPegfilgrastim’ to cancer patients in developed markets like the US & EU regions. With this, it has become the only Indian company to do so.     

The company aims to deliver substantial savings to healthcare systems by enhancing access and availability of these high-quality, affordable biosimilar cancer therapies in 25 countries in Africa and 5 countries in Asia currently covered under CAP, led by Clinton Health Access Initiative.  

On Friday, the stock of Biocon Limited closed at Rs 407.25 per share, down by 0.59 per cent or 2.40 per share. The 52-week high is recorded at Rs 487.70 while its 52-week low is Rs 235.80 on BSE.